Screening lead compounds for QT interval prolongation.

Drug Discov Today

GENION Forschungsgesellschaft mbH Abteistrasse 57 20149, Hamburg, Germany

Published: January 2001

AI Article Synopsis

Article Abstract

The late detection of cardiotoxic side effects, such as QT prolongation, induced by compounds of pharmacological interest can dramatically impede drug discovery and development projects, and consequently increase their cost. The launch of new drugs with undetected cardiotoxic side effects could have hazardous consequences and could trigger lethal cardiac dysrhythmias in patients. It is desirable, therefore, to test for the potential cardiotoxic side effects of compounds at an early stage of drug development. Electrophysiological test systems and cellular-based fluorometric high-throughput assays are now available for cloned human cardiac ion channels. These test systems are important tools in the preclinical safety evaluation of drugs and newly developed compounds.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s1359-6446(00)01602-0DOI Listing

Publication Analysis

Top Keywords

cardiotoxic side
12
side effects
12
test systems
8
screening lead
4
compounds
4
lead compounds
4
compounds interval
4
interval prolongation
4
prolongation late
4
late detection
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!